TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01776307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 is administered at 500 mg po bid continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 is administered at 500 mg po bid continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 is administered at 500 mg po bid continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
Study: NCT01158170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Description: 25GY/10fraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib /Gefitinib
Description: Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib /Gefitinib
Description: Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
Study: NCT01105546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant activated factor VII
Description: 90 µg/kg/day i.v.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant activated factor VII
Description: treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
Study: NCT02499133

Intervention type: OTHER
Group type: OTHER
Intervention: language and cognitive tests
Description: The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.

Intervention type: OTHER
Group type: OTHER
Intervention: language and cognitive tests
Description: The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
Study: NCT04042090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reducept, virtual reality
Description: The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
Study: NCT01835509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention, Camp plus reunions
Study: NCT01363349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP-1020
Description: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study: NCT01958489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Administered orally
Study: NCT01717833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NEMS
Description: NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham sessions of neuromuscular electrical stimulation
Study: NCT00573144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 72 hours of saline solution (packaged to match active comparator)
Study: NCT03569345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFXl-assisted ingenol mebutate delivery
Description: Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30.
Study: NCT00644007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a substitute of SK3530 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK3530
Description: SK3530 100 mg
Study: NCT01529138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Combination treatment with temsirolimus and axitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Combination treatment with temsirolimus and axitinib
Study: NCT01087736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
Study: NCT02120040

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of anxiety with psychosocial scales
Study: NCT02780011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alsertib
Description: Aurora A kinase inhibitor
Study: NCT02238067

Intervention type: DRUG
Intervention: ESA
Description: Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.

Intervention type: OTHER
Intervention: Satisfaction Survey Questionnaire
Description: Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
Study: NCT03083990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI305(Bevacizumab Biosimilar)
Description: 3mg/kg, infusion in 90minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin(Bevacizumab)
Description: 3mg/kg, infusion in 90minutes
Study: NCT01430442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rimegepant placebo-matching capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
Study: NCT02975843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
Description: single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
Study: NCT02700737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-based simulation modelling
Description: The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaging parameters currently recommended by clinical practice guidelines
Description: The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging parameters currently recommended by clinical practice guidelines
Description: The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset).
Study: NCT00185393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)
Description: treatment with 90 Yttrium-labeled anti CD 20 antibody

Intervention type: OTHER
Group type: OTHER
Intervention: no treatment
Description: no treatment
Study: NCT03363633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium tetradecyl sulfate
Description: Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression
Description: 20-30 mmHg compression stockings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression
Description: 20-30 mmHg compression stockings
Study: NCT03591380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
Study: NCT03674151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nylon dressing
Description: Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manuka-Honey
Description: Manuka-Honey dressing on split-skin grafted third-degree burn wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iod (PVP-Iod)
Description: Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Hydrogel dressing on split-skin grafted third-degree burn wound
Study: NCT01708980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six different strength training exercises
Description: Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
Study: NCT01265459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml
Description: Durolane is an intraarticular hyaluronic acid preparation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml
Description: Durolane is an intraarticular hyaluronic acid preparation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml
Description: Durolane is an intraarticular hyaluronic acid preparation
Study: NCT02816918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraluminal use of Univent bronchial Blocker
Description: Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innerluminal use Univent bronchial Blocker
Description: Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
Study: NCT01935843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-HER-2
Study: NCT01014117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
Study: NCT04638491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin for injection
Description: On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
Study: NCT01874171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT01775631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab
Study: NCT00664001

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anti-oxidant supplementation
Description: Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo for anti-oxidant supplementation
Description: Matched placebo for anti-oxidant supplementation
Study: NCT02801019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-poly
Description: comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-poly
Description: comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ArComXL
Description: comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ArComXL
Description: comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
Study: NCT00863213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
Study: NCT00448643

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Brachytherapy
Description: High-Dose Rate \[HDR\] or Low-Dose Rate \[LDR\], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Abdominal Radiation [WAR] Therapy
Description: Whole Abdominal Radiation Therapy, Dose Escalated \[2-Levels\]; 6 -8 hours after administration of Cisplatin chemotherapy
Study: NCT00197548

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins-vitamins B-complex, C, and E
Description: One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
Study: NCT01090323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Description: Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
Study: NCT01324037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic algorithm
Description: diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
Study: NCT03162367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous epidermal cell suspension
Description: First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver sulfadiazine ointment
Description: the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
Study: NCT01082549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin plus Iniparib
Description: i.v.